| Symbol | VNDA |
|---|---|
| Name | VANDA PHARMACEUTICALS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2200 PENNSYLVANIA AVENUE NW,SUITE 300 E, WASHINGTON, District of Columbia, 20037, United States |
| Telephone | +1 202 734-3400 |
| Fax | — |
| — | |
| Website | https://www.vandapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001347178 |
| Description | Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Additional info from NASDAQ: |
2026-08-22 19:16
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Read more
2026-08-19 19:33
New Form SCHEDULE 13G - Vanda Pharmaceuticals Inc. <b>Filed:</b> 2026-08-19 <b>AccNo:</b> 0001104659-26-098866 <b>Size:</b> 15 KB
Read more
2026-08-13 10:23
New Form SCHEDULE 13G - Vanda Pharmaceuticals Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001167557-26-000170 <b>Size:</b> 8 KB
Read more
2026-07-16 20:30
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Read more
2026-07-15 20:30
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
Read more
2026-07-07 20:30
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Read more
2026-06-08 20:39
McGuire Daniel Patrick 🟢 acquired 80.0K shares of Vanda Pharmaceuticals Inc. (VNDA) Transaction Date: Jun 04, 2026 | Filing ID: 261871
Read more
2026-06-08 20:23
Chrousos Phaedra 🟢 acquired 41.6K shares of Vanda Pharmaceuticals Inc. (VNDA) Transaction Date: Jun 04, 2026 | Filing ID: 261811
Read more
2026-06-08 20:21
Duncan Charles Cliff 🟢 acquired 41.6K shares of Vanda Pharmaceuticals Inc. (VNDA) Transaction Date: Jun 04, 2026 | Filing ID: 261806
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04474990 | Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient Wit… | — | Gastroparesis | Available | — | — | ClinicalTrials.gov |
| NCT00467441 | VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sl… | Phase2 | Excessive Somnolence | Completed | — | — | ClinicalTrials.gov |
| NCT07686081 | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients Wi… | Phase3 | Ulcerative Colitis (UC) | Recruiting | 2026-09-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT07446439 | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-… | Phase3 | Nausea and Vomiting | Recruiting | 2026-03-27 | 2026-12-01 | ClinicalTrials.gov |
| NCT07362017 | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderat… | Phase3 | Moderate-to-severe Chronic Plaque Psoriasis | Recruiting | 2026-02-17 | 2028-12-01 | ClinicalTrials.gov |
| NCT07179055 | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to … | Phase2 | Dry Eye | Recruiting | 2025-10-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT07221578 | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatmen… | Phase3 | Social Anxiety Disorder (SAD) | Active_Not_Recruiting | 2025-09-22 | 2027-04-01 | ClinicalTrials.gov |
| NCT07090161 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participa… | Phase2 | Hypertension | Recruiting | 2025-09-15 | 2026-11-01 | ClinicalTrials.gov |
| NCT06961968 | Randomized Withdrawal Study in Patients With Schizophrenia | Phase3 | Schizophrenia | Recruiting | 2025-05-14 | 2027-11-01 | ClinicalTrials.gov |
| NCT07223632 | Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individ… | Phase1 | Charcot Marie Tooth Disease (CMT) | Active_Not_Recruiting | 2025-05-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT07065773 | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Se… | Phase2 | Onychomycosis of Toenail | Active_Not_Recruiting | 2025-05-05 | 2026-09-01 | ClinicalTrials.gov |
| NCT06953869 | Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | Phase3 | Insomnia Disorder | Recruiting | 2025-04-21 | 2028-01-01 | ClinicalTrials.gov |
| NCT06830044 | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Pat… | Phase3 | Major Depressive Disorder (MDD) | Recruiting | 2025-03-03 | 2028-03-01 | ClinicalTrials.gov |
| NCT06804603 | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting Afte… | Phase2 | Obesity | Completed | 2025-02-25 | 2025-10-06 | ClinicalTrials.gov |
| NCT06701396 | Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase D… | Phase3 | Sleep Wake Disorders | Recruiting | 2024-10-08 | 2025-06-30 | ClinicalTrials.gov |
| NCT06494397 | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Con… | Phase1 | Schizophrenia | Completed | 2024-07-11 | 2024-10-24 | ClinicalTrials.gov |
| NCT06296966 | A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in t… | Phase2 | Dry Eye | Unknown | 2024-02-29 | 2024-07-01 | ClinicalTrials.gov |
| NCT06836557 | Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | Phase3 | Idiopathic Gastroparesis | Recruiting | 2024-01-09 | 2025-12-01 | ClinicalTrials.gov |
| NCT05922995 | The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD) | Early_Phase1 | REM Behavior Disorder | Terminated | 2023-09-30 | 2023-12-01 | ClinicalTrials.gov |
| NCT05903924 | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participa… | Phase3 | Motion Sickness | Completed | 2023-09-09 | 2024-04-24 | ClinicalTrials.gov |
| NCT05648591 | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents | Phase4 | Schizophrenia | Recruiting | 2023-05-24 | 2026-11-30 | ClinicalTrials.gov |
| NCT06138613 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants … | Phase3 | Motion Sickness | Active_Not_Recruiting | 2023-02-27 | 2027-12-30 | ClinicalTrials.gov |
| NCT06803290 | Food Effect Study of VHX-896 in Healthy Volunteers | Phase1 | Healthy | Completed | 2022-06-21 | 2022-12-27 | ClinicalTrials.gov |
| NCT05344365 | A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psycho… | Phase2 | Parkinson Disease Psychosis | Withdrawn | 2022-06-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT05572281 | Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspens… | Phase1 | Healthy | Completed | 2022-05-18 | 2022-06-15 | ClinicalTrials.gov |
| NCT05366855 | Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in … | Phase3 | Generalized Pustular Psoriasis | Terminated | 2022-04-21 | 2024-07-12 | ClinicalTrials.gov |
| NCT05352893 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatm… | Phase3 | Generalized Pustular Psoriasis | Completed | 2022-04-14 | 2023-08-17 | ClinicalTrials.gov |
| NCT04327661 | Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Af… | Phase3 | Motion Sickness | Completed | 2021-11-15 | 2023-04-12 | ClinicalTrials.gov |
| NCT05361707 | Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disor… | Phase3 | Autism Spectrum Disorder | Unknown | 2021-07-28 | 2025-07-01 | ClinicalTrials.gov |
| NCT04856930 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Trea… | Phase2 | Hidradenitis Suppurativa | Completed | 2021-07-07 | 2022-12-14 | ClinicalTrials.gov |
| NCT04969211 | Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy… | Phase1 | Healthy | Completed | 2021-06-30 | 2021-10-13 | ClinicalTrials.gov |
| NCT04856917 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Trea… | Phase2 | Acne Vulgaris | Completed | 2021-05-15 | 2022-03-29 | ClinicalTrials.gov |
| NCT04697069 | A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the T… | Phase2 | Acneiform Eruptions | Terminated | 2021-05-04 | 2021-12-13 | ClinicalTrials.gov |
| NCT04819776 | Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Mani… | Phase3 | Bipolar I Disorder | Completed | 2021-03-22 | 2023-08-16 | ClinicalTrials.gov |
| NCT04800237 | Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety | Phase2 | Performance Anxiety | Completed | 2021-02-23 | 2022-08-02 | ClinicalTrials.gov |
| NCT04849559 | Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and… | Phase1 | Healthy Volunteer | Completed | 2021-02-01 | 2021-09-24 | ClinicalTrials.gov |
| NCT04697056 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Trea… | Phase2 | Ichthyosis | Terminated | 2021-01-25 | 2021-11-19 | ClinicalTrials.gov |
| NCT04712734 | A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment o… | Phase1 | Schizophrenia | Completed | 2021-01-13 | 2022-08-30 | ClinicalTrials.gov |
| NCT04652882 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase D… | Phase3 | Sleep Wake Disorders | Active_Not_Recruiting | 2020-12-09 | 2026-09-01 | ClinicalTrials.gov |
| NCT04622345 | Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in A… | Phase2 | Allergic Conjunctivitis | Completed | 2020-11-21 | 2021-06-28 | ClinicalTrials.gov |
| NCT04353401 | WGS Analysis of COVID-19 Positive Patients | — | Coronavirus Infection | Completed | 2020-08-03 | 2022-03-09 | ClinicalTrials.gov |
| NCT04326426 | ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe … | Phase3 | Coronavirus Infection | Enrolling_By_Invitation | 2020-04-13 | 2020-08-31 | ClinicalTrials.gov |
| NCT04140695 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) | Phase3 | Atopic Dermatitis | Terminated | 2019-10-21 | 2020-10-14 | ClinicalTrials.gov |
| NCT04127058 | Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizoph… | Phase1 | Bipolar I Disorder | Completed | 2019-10-07 | 2019-11-27 | ClinicalTrials.gov |
| NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and… | Phase3 | Idiopathic Gastroparesis | Completed | 2019-08-20 | 2025-02-21 | ClinicalTrials.gov |
| NCT03633396 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults W… | Phase2 | Palmoplantar Pustulosis | Completed | 2019-05-20 | 2021-04-23 | ClinicalTrials.gov |
| NCT03619902 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults W… | Phase2 | Generalized Pustular Psoriasis | Completed | 2019-01-30 | 2021-01-20 | ClinicalTrials.gov |
| NCT03772340 | Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects A… | Phase2 | Motion Sickness | Completed | 2018-12-20 | 2019-06-27 | ClinicalTrials.gov |
| NCT03838926 | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory He… | Phase1 | Relapsed or Refractory Hematologic Malignancies | Recruiting | 2018-09-27 | 2027-12-01 | ClinicalTrials.gov |
| NCT06323655 | Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo an… | Phase1 | Healthy Volunteers | Completed | 2018-07-19 | 2018-08-28 | ClinicalTrials.gov |
| NCT03568331 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) | Phase3 | Atopic Dermatitis | Completed | 2018-07-09 | 2019-12-27 | ClinicalTrials.gov |
| NCT03373201 | Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia | Phase3 | Jet Lag Type Insomnia | Completed | 2017-10-16 | 2018-03-05 | ClinicalTrials.gov |
| NCT02970968 | Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis | Phase2 | Gastroparesis | Completed | 2016-11-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02776215 | Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolesc… | Phase1 | Circadian Rhythm Sleep Disorders | Completed | 2016-10-04 | 2017-12-20 | ClinicalTrials.gov |
| NCT03291041 | A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in … | Phase2 | Jet Lag Disorder | Completed | 2016-07-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02651714 | Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2016-01-19 | 2017-08-04 | ClinicalTrials.gov |
| NCT03154697 | Development of Clinical Database of Individuals With Smith-Magenis Syndrome and… | — | Sleep Disturbances in Smith-Magenis Syndrome | Recruiting | 2016-01-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT02621385 | Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Mid… | Phase1 | Healthy Volunteers | Completed | 2015-11-01 | — | ClinicalTrials.gov |
| NCT02231008 | Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS | Phase2 | Smith-Magenis Syndrome | Completed | 2015-09-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT02560103 | An Observational Study to Investigate the Effects of Rapid Transmeridian Travel | — | Jet Lag Disorder | Completed | 2015-09-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02180451 | Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms… | — | Smith Magenis Syndrome | Unknown | 2014-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02130999 | Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ… | Phase4 | Non-24-Hour-Sleep-Wake Disorder | Completed | 2014-05-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02004041 | Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Assoc… | Phase2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | Completed | 2013-12-10 | 2015-02-19 | ClinicalTrials.gov |
| NCT01919944 | Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Inject… | Phase1 | Pruritus | Completed | 2013-08-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01637636 | Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibito… | Phase1 | Healthy | Completed | 2012-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01578057 | Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelte… | Phase1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | Completed | 2012-04-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01540500 | Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor,… | Phase1 | Healthy Volunteers | Completed | 2012-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01526746 | Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched C… | Phase1 | Renal Impairment | Completed | 2012-02-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01477619 | Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerabil… | Phase1 | Healthy Volunteers | Completed | 2011-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01495169 | Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients | Phase1 | Safety and Tolerability of Iloperidone | Completed | 2011-10-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01429116 | Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in B… | Phase3 | Non-24-Hour Sleep-Wake Disorder | Completed | 2011-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01430754 | Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-… | Phase3 | Non-24-Hour Sleep-Wake Disorder | Completed | 2011-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01428661 | Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major … | Phase2 | Major Depressive Disorder | Completed | 2011-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01402076 | A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enz… | Phase1 | Healthy Volunteers | Completed | 2011-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01291511 | Relapse Prevention Study in Patients With Schizophrenia | Phase3 | Schizophrenia | Completed | 2011-02-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01271387 | Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impai… | Phase1 | Hepatic Impairment | Completed | 2011-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01218789 | Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in… | Phase3 | Non 24 Hour Sleep Wake Disorder | Active_Not_Recruiting | 2010-10-28 | 2024-12-05 | ClinicalTrials.gov |
| NCT01163032 | Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subje… | Phase3 | Non-24-Hour Sleep-Wake Disorder | Completed | 2010-08-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01195558 | Patient Registry of Blind Subjects With Sleep-related Problems | — | Sleep-wake Disorder in Blind Individuals | Recruiting | 2010-04-01 | 2030-04-01 | ClinicalTrials.gov |
| NCT00548340 | VEC-162 Study in Adult Patients With Primary Insomnia | Phase3 | Primary Insomnia | Completed | 2007-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00291187 | VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia | Phase3 | Insomnia | Completed | 2006-02-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00254202 | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in … | Phase3 | Schizophrenia | Completed | 2005-11-18 | 2007-03-21 | ClinicalTrials.gov |
| NCT00490945 | Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers | Phase2 | Circadian Rhythm Sleep Disorders | Completed | 2004-07-01 | 2005-03-01 | ClinicalTrials.gov |
Total clinical trials: 83
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| VCA-894A | Other | Phase PHASE1 | Charcot Marie Tooth Disease (CMT) | ACTIVE_NOT_RECRUITING | NCT07223632 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis (UC) | RECRUITING | NCT07686081 |
| Ponesimod | Other | Phase PHASE3 | Ulcerative Colitis (UC) | RECRUITING | NCT07686081 |
| Placebo | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT07221578 |
| VQW-765 | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT07221578 |
| Placebo | Other | Phase PHASE3 | Sleep Wake Disorders | ACTIVE_NOT_RECRUITING | NCT04652882 |
| Tasimelteon | Other | Phase PHASE3 | Sleep Wake Disorders | ACTIVE_NOT_RECRUITING | NCT04652882 |
| Placebo | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT07221578 |
| VQW-765 | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT07221578 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis (UC) | NOT_YET_RECRUITING | NCT07686081 |
| Ponesimod | Other | Phase PHASE3 | Ulcerative Colitis (UC) | NOT_YET_RECRUITING | NCT07686081 |
| Placebo | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| VQW-765 | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| Ponesimod | Other | Phase PHASE3 | Moderate-to-severe Chronic Plaque Psoriasis | RECRUITING | NCT07362017 |
| Placebo | Other | Phase PHASE3 | Insomnia Disorder | RECRUITING | NCT06953869 |
| Tasimelteon Oral Suspension | Other | Phase PHASE3 | Insomnia Disorder | RECRUITING | NCT06953869 |
| Placebo | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| VQW-765 | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01428661 |
| tasimelteon | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01428661 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT03568331 |
| Tradipitant | Other | Phase PHASE3 | Atopic Dermatitis | COMPLETED | NCT03568331 |
| placebo | Other | Phase PHASE2 | Ichthyosis | TERMINATED | NCT04697056 |
| Imsidolimab | Other | Phase PHASE2 | Ichthyosis | TERMINATED | NCT04697056 |
| Ketoconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01637636 |
| Rifampin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01637636 |
| tasimelteon | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01637636 |
| Placebo ethanol | Other | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| Placebo tasimelteon | Other | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| Ethanol | Other | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| tasimelteon | Other | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| Fluvoxamine | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01540500 |
| Tasimelteon | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01540500 |
| Tasimelteon | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT01526746 |
| Tasimelteon | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01477619 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01402076 |
| Rosiglitazone | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01402076 |
| Tasimelteon | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01402076 |
| tasimelteon | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01271387 |
| Placebo | Other | Phase PHASE3 | Non-24-Hour Sleep-Wake Disorder | COMPLETED | NCT01430754 |
| tasimelteon | Other | Phase PHASE3 | Non-24-Hour Sleep-Wake Disorder | COMPLETED | NCT01430754 |
| Placebo | Other | Phase PHASE3 | Non-24-Hour Sleep-Wake Disorder | COMPLETED | NCT01163032 |
| tasimelteon | Other | Phase PHASE3 | Non-24-Hour Sleep-Wake Disorder | COMPLETED | NCT01163032 |
| tasimelteon | Other | Phase PHASE3 | Non-24-Hour Sleep-Wake Disorder | COMPLETED | NCT01429116 |
| Placebo | Other | Phase PHASE1 | Pruritus | COMPLETED | NCT01919944 |
| VLY-686 | Other | Phase PHASE1 | Pruritus | COMPLETED | NCT01919944 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02621385 |
| tradipitant | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02621385 |
| iloperidone (oral tablet) | Other | Phase PHASE1 | Safety and Tolerability of Iloperidone | COMPLETED | NCT01495169 |
| tasimelteon 2 mg I.V. | Other | Phase PHASE4 | Non-24-Hour-Sleep-Wake Disorder | COMPLETED | NCT02130999 |
| tasimelteon 20 mg capsule | Other | Phase PHASE4 | Non-24-Hour-Sleep-Wake Disorder | COMPLETED | NCT02130999 |
| Transmeridian travel across multiple time zones | Other | Preclinical | Jet Lag Disorder | COMPLETED | NCT02560103 |
| Iloperidone | Other | Phase PHASE1 | Bipolar I Disorder | COMPLETED | NCT04127058 |
| Placebo | Other | Phase PHASE3 | Coronavirus Infection | ENROLLING_BY_INVITATION | NCT04326426 |
| Tradipitant | Other | Phase PHASE3 | Coronavirus Infection | ENROLLING_BY_INVITATION | NCT04326426 |
| Data collection on blindness and sleep problems | Other | Preclinical | Sleep-wake Disorder in Blind Individuals | RECRUITING | NCT01195558 |
| Placebo | Other | Phase PHASE2 | Jet Lag Disorder | COMPLETED | NCT03291041 |
| Tasimelteon | Other | Phase PHASE2 | Jet Lag Disorder | COMPLETED | NCT03291041 |
| Iloperidone and VHX-896 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04969211 |
| VHX-896 and iloperidone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04969211 |
| placebo | Other | Phase PHASE2 | Smith-Magenis Syndrome | COMPLETED | NCT02231008 |
| tasimelteon | Other | Phase PHASE2 | Smith-Magenis Syndrome | COMPLETED | NCT02231008 |
| Iloperidone | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT04712734 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01291511 |
| Iloperidone | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT01291511 |
| Placebo | Other | Phase PHASE3 | Jet Lag Type Insomnia | COMPLETED | NCT03373201 |
| Tasimelteon | Other | Phase PHASE3 | Jet Lag Type Insomnia | COMPLETED | NCT03373201 |
| Placebo | Other | Phase PHASE2 | Dry Eye | UNKNOWN | NCT06296966 |
| VSJ-110 | Other | Phase PHASE2 | Dry Eye | UNKNOWN | NCT06296966 |
| Placebo | Other | Phase PHASE2 | Performance Anxiety | COMPLETED | NCT04800237 |
| VQW-765 | Other | Phase PHASE2 | Performance Anxiety | COMPLETED | NCT04800237 |
| Data collection of sleep disturbances in individuals with SMS | Other | Preclinical | Sleep Disturbances in Smith-Magenis Syndrome | RECRUITING | NCT03154697 |
| Active Control | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Tasimelteon Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Active Control Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Tasimelteon | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Tasimelteon Oral Suspension | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05572281 |
| Tasimelteon Oral Capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05572281 |
| Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Other | Phase PHASE3 | Autism Spectrum Disorder | UNKNOWN | NCT05361707 |
| Iloperidone | Other | Phase PHASE2 | Parkinson Disease Psychosis | WITHDRAWN | NCT05344365 |
| tasimelteon | Other | Phase PHASE1 | Circadian Rhythm Sleep Disorders | COMPLETED | NCT02776215 |
| tasimelteon | Other | Phase PHASE3 | Non 24 Hour Sleep Wake Disorder | ACTIVE_NOT_RECRUITING | NCT01218789 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04849559 |
| Tradipitant | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04849559 |
| Iloperidone Placebo | Other | Phase PHASE3 | Bipolar I Disorder | COMPLETED | NCT04819776 |
| Iloperidone | Other | Phase PHASE3 | Bipolar I Disorder | COMPLETED | NCT04819776 |
| Placebo | Other | Phase PHASE3 | Atopic Dermatitis | TERMINATED | NCT04140695 |
| Tradipitant | Other | Phase PHASE3 | Atopic Dermatitis | TERMINATED | NCT04140695 |
| Placebo | Other | Phase PHASE2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | COMPLETED | NCT02004041 |
| VLY-686 | Other | Phase PHASE2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | COMPLETED | NCT02004041 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT02651714 |
| Tradipitant | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT02651714 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02970968 |
| VLY-686 (Tradipitant) | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02970968 |
| Placebo | Other | Phase PHASE3 | Sleep Wake Disorders | RECRUITING | NCT06701396 |
| Tasimelteon | Other | Phase PHASE3 | Sleep Wake Disorders | RECRUITING | NCT06701396 |
| Placebo | Other | Phase PHASE3 | Motion Sickness | COMPLETED | NCT04327661 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | COMPLETED | NCT04327661 |
| VHX-896 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06803290 |
| Tradipitant | Other | Phase PHASE3 | Idiopathic Gastroparesis | RECRUITING | NCT06836557 |
| Iloperidone | Other | Phase PHASE4 | Schizophrenia | RECRUITING | NCT05648591 |
| Placebo | Other | Phase PHASE3 | Motion Sickness | COMPLETED | NCT05903924 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | COMPLETED | NCT05903924 |
| Placebo | Other | Phase PHASE3 | Insomnia Disorder | RECRUITING | NCT06953869 |
| Tasimelteon Oral Suspension | Other | Phase PHASE3 | Insomnia Disorder | RECRUITING | NCT06953869 |
| Placebo | Other | Phase PHASE2 | Motion Sickness | COMPLETED | NCT03772340 |
| Tradipitant | Other | Phase PHASE2 | Motion Sickness | COMPLETED | NCT03772340 |
| Open Label Tradipitant | Other | Phase PHASE3 | Idiopathic Gastroparesis | COMPLETED | NCT04028492 |
| Placebo | Other | Phase PHASE3 | Idiopathic Gastroparesis | COMPLETED | NCT04028492 |
| Tradipitant | Other | Phase PHASE3 | Idiopathic Gastroparesis | COMPLETED | NCT04028492 |
| Tradipitant | Other | Preclinical | Gastroparesis | AVAILABLE | NCT04474990 |
| Placebo | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT04622345 |
| VSJ-110 | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT04622345 |
| Placebo | Other | Phase PHASE2 | Palmoplantar Pustulosis | COMPLETED | NCT03633396 |
| Imsidolimab | Other | Phase PHASE2 | Palmoplantar Pustulosis | COMPLETED | NCT03633396 |
| Imsidolimab | Other | Phase PHASE2 | Generalized Pustular Psoriasis | COMPLETED | NCT03619902 |
| Placebo | Other | Phase PHASE2 | Dry Eye | RECRUITING | NCT07179055 |
| VSJ-110 | Other | Phase PHASE2 | Dry Eye | RECRUITING | NCT07179055 |
| Iloperidone and VHX-896 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT06494397 |
| VHX-896 and iloperidone | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT06494397 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT04856930 |
| Imsidolimab | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT04856930 |
| Placebo | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04856917 |
| Imsidolimab | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04856917 |
| Placebo | Other | Phase PHASE2 | Acneiform Eruptions | TERMINATED | NCT04697069 |
| Imsidolimab | Other | Phase PHASE2 | Acneiform Eruptions | TERMINATED | NCT04697069 |
| Tasimelteon | Other | Phase EARLY_PHASE1 | REM Behavior Disorder | TERMINATED | NCT05922995 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06804603 |
| Tradipitant | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06804603 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | ACTIVE_NOT_RECRUITING | NCT06138613 |
| VCA-894A | Other | Phase PHASE1 | Charcot Marie Tooth Disease (CMT) | ACTIVE_NOT_RECRUITING | NCT07223632 |
| Placebo | Other | Phase PHASE3 | Sleep Wake Disorders | RECRUITING | NCT04652882 |
| Tasimelteon | Other | Phase PHASE3 | Sleep Wake Disorders | RECRUITING | NCT04652882 |
| placebo | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT06961968 |
| iloperidone | Other | Phase PHASE3 | Schizophrenia | RECRUITING | NCT06961968 |
| Ponesimod | Other | Phase PHASE3 | Moderate-to-severe Chronic Plaque Psoriasis | NOT_YET_RECRUITING | NCT07362017 |
| Trichostatin A | Other | Phase PHASE2 | Onychomycosis of Toenail | ACTIVE_NOT_RECRUITING | NCT07065773 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07090161 |
| iloperidone | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07090161 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder (MDD) | RECRUITING | NCT06830044 |
| Milsaperidone | Other | Phase PHASE3 | Major Depressive Disorder (MDD) | RECRUITING | NCT06830044 |
| Trichostatin A | Other | Phase PHASE1 | Relapsed or Refractory Hematologic Malignancies | RECRUITING | NCT03838926 |
| Placebo | Other | Phase PHASE3 | Generalized Pustular Psoriasis | COMPLETED | NCT05352893 |
| 300 mg Imsidolimab | Other | Phase PHASE3 | Generalized Pustular Psoriasis | COMPLETED | NCT05352893 |
| 750 mg Imsidolimab | Other | Phase PHASE3 | Generalized Pustular Psoriasis | COMPLETED | NCT05352893 |
| Imsidolimab 750 mg IV/200 mg SC | Other | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Standard of Care (SOC) | Other | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Open-label 200 mg imsidolimab | Other | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Placebo | Other | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Double-blind 200 mg imsidolimab | Other | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Placebo | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| VQW-765 | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| Placebo | Other | Phase PHASE3 | Nausea and Vomiting | RECRUITING | NCT07446439 |
| Tradipitant | Other | Phase PHASE3 | Nausea and Vomiting | RECRUITING | NCT07446439 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | ACTIVE_NOT_RECRUITING | NCT06138613 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | ACTIVE_NOT_RECRUITING | NCT06138613 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | ACTIVE_NOT_RECRUITING | NCT06138613 |
| Tradipitant | Other | Phase PHASE3 | Motion Sickness | ACTIVE_NOT_RECRUITING | NCT06138613 |
| Crushed d-amphetamine sulfate IR tablets | DRUG | Phase PHASE1 | ADHD | COMPLETED | NCT04232644 |
| ADAIR 10mg IR capsules | DRUG | Phase PHASE1 | ADHD | COMPLETED | NCT04232644 |
| d-amphetamine sulfate | DRUG | Phase PHASE1 | ADHD | COMPLETED | NCT04647903 |
| ADAIR 10 mg IR tablets | DRUG | Phase PHASE1 | ADHD | COMPLETED | NCT04647903 |
| Ponesimod | DRUG | Phase PHASE3 | Moderate-to-severe Chronic Plaque Psoriasis | NOT_YET_RECRUITING | NCT07362017 |
| VCA-894A | DRUG | Phase PHASE1 | Charcot Marie Tooth Disease (CMT) | ACTIVE_NOT_RECRUITING | NCT07223632 |
| iloperidone | DRUG | Phase PHASE2 | Hypertension | RECRUITING | NCT07090161 |
| Milsaperidone | DRUG | Phase PHASE3 | Major Depressive Disorder (MDD) | RECRUITING | NCT06830044 |
| VHX-896 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06803290 |
| Active Control | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Tasimelteon Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Active Control Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06323655 |
| Tasimelteon Oral Suspension | DRUG | Phase PHASE3 | Insomnia Disorder | RECRUITING | NCT06953869 |
| Tasimelteon Oral Capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05572281 |
| Imsidolimab 750 mg IV/200 mg SC | DRUG | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Standard of Care (SOC) | OTHER | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Open-label 200 mg imsidolimab | DRUG | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Double-blind 200 mg imsidolimab | DRUG | Phase PHASE3 | Generalized Pustular Psoriasis | TERMINATED | NCT05366855 |
| Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | DRUG | Phase PHASE3 | Autism Spectrum Disorder | RECRUITING | NCT05361707 |
| 300 mg Imsidolimab | DRUG | Phase PHASE3 | Generalized Pustular Psoriasis | COMPLETED | NCT05352893 |
| 750 mg Imsidolimab | DRUG | Phase PHASE3 | Generalized Pustular Psoriasis | COMPLETED | NCT05352893 |
| Iloperidone and VHX-896 | DRUG | Phase PHASE1 | Schizophrenia | COMPLETED | NCT06494397 |
| VHX-896 and iloperidone | DRUG | Phase PHASE1 | Schizophrenia | COMPLETED | NCT06494397 |
| Iloperidone Placebo | DRUG | Phase PHASE3 | Bipolar I Disorder | COMPLETED | NCT04819776 |
| VQW-765 | DRUG | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT07221578 |
| VSJ-110 | DRUG | Phase PHASE2 | Dry Eye | RECRUITING | NCT07179055 |
| Open Label Tradipitant | DRUG | Phase PHASE3 | Idiopathic Gastroparesis | COMPLETED | NCT04028492 |
| Trichostatin A | DRUG | Phase PHASE2 | Onychomycosis of Toenail | ACTIVE_NOT_RECRUITING | NCT07065773 |
| Imsidolimab | BIOLOGICAL | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT04856930 |
| Data collection of sleep disturbances in individuals with SMS | OTHER | Preclinical | Sleep Disturbances in Smith-Magenis Syndrome | RECRUITING | NCT03154697 |
| VLY-686 (Tradipitant) | DRUG | Phase PHASE2 | Gastroparesis | COMPLETED | NCT02970968 |
| Tradipitant | DRUG | Phase PHASE3 | Nausea and Vomiting | NOT_YET_RECRUITING | NCT07446439 |
| tradipitant | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02621385 |
| Transmeridian travel across multiple time zones | OTHER | Preclinical | Jet Lag Disorder | COMPLETED | NCT02560103 |
| tasimelteon 2 mg I.V. | DRUG | Phase PHASE4 | Non-24-Hour-Sleep-Wake Disorder | COMPLETED | NCT02130999 |
| tasimelteon 20 mg capsule | DRUG | Phase PHASE4 | Non-24-Hour-Sleep-Wake Disorder | COMPLETED | NCT02130999 |
| VLY-686 | DRUG | Phase PHASE2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | COMPLETED | NCT02004041 |
| Ketoconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01637636 |
| Rifampin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01637636 |
| Placebo ethanol | DRUG | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| Placebo tasimelteon | OTHER | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| Ethanol | DRUG | Phase PHASE1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol | COMPLETED | NCT01578057 |
| Fluvoxamine | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01540500 |
| iloperidone (oral tablet) | DRUG | Phase PHASE1 | Safety and Tolerability of Iloperidone | COMPLETED | NCT01495169 |
| placebo | DRUG | Phase PHASE3 | Schizophrenia | RECRUITING | NCT06961968 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02621385 |
| Rosiglitazone | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01402076 |
| Tasimelteon | DRUG | Phase PHASE3 | Sleep Wake Disorders | RECRUITING | NCT06701396 |
| Data collection on blindness and sleep problems | OTHER | Preclinical | Sleep-wake Disorder in Blind Individuals | RECRUITING | NCT01195558 |
| tasimelteon | DRUG | Phase PHASE1 | Circadian Rhythm Sleep Disorders | COMPLETED | NCT02776215 |
| VEC-162 50 mg | DRUG | Phase PHASE3 | Primary Insomnia | COMPLETED | NCT00548340 |
| VEC-162 20 mg | DRUG | Phase PHASE3 | Primary Insomnia | COMPLETED | NCT00548340 |
| VEC-162 | DRUG | Phase PHASE2 | Circadian Rhythm Sleep Disorders | COMPLETED | NCT00490945 |
| VSF-173 | DRUG | Phase PHASE2 | Excessive Somnolence | COMPLETED | NCT00467441 |
| 100 mg VEC-162 | DRUG | Phase PHASE3 | Insomnia | COMPLETED | NCT00291187 |
| 50 mg VEC-162 | DRUG | Phase PHASE3 | Insomnia | COMPLETED | NCT00291187 |
| 20 mg VEC-162 | DRUG | Phase PHASE3 | Insomnia | COMPLETED | NCT00291187 |
| Placebo | DRUG | Phase PHASE1 | ADHD | COMPLETED | NCT04647903 |
| Ziprasidone | DRUG | Phase PHASE3 | Schizophrenia | COMPLETED | NCT00254202 |
| Iloperidone | DRUG | Phase PHASE4 | Schizophrenia | RECRUITING | NCT05648591 |
Total products: 218